Hereditary Colorectal Cancer Syndromes: ASCO Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: ESMO Clinical Practice Guidelines Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, April 26, 2016

Hereditary Colorectal Cancer Syndromes: ASCO Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: ESMO Clinical Practice Guidelines



 Blogger's Note: excerpt below as it applies to CA125/extracolonic surveillance

 open access
Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines http://ovariancancerandus.blogspot.com/feeds/posts/default
 
ASCO Surveillance Recommendations
ESMO recommendations, with original language, are listed below with qualifying statements added by the ASCO Endorsement Panel listed in bold italics (Data Supplement 2 provides ESMO recommendations, reprinted with permission).1
Lynch syndrome
  • Colon and rectum: Colonoscopy every 1 to 2 years, starting at age 20 to 25 or 5 years before the youngest case in the family. No upper limit is established.
  • Endometrium and ovary: Gynecological examination, pelvic ultrasound (not CA-125), and aspiration biopsy every year, from age 30 to 35 years. Consider prophylactic hysterectomy and salpingoophorectomy when childbearing is completed.
  • Gastric cancer: For gastric cancer, the search for the presence of Helicobacter pylori and subsequent eradication is recommended in mutation carriers. In case of a high incidence of gastric cancer in some populations, some experts recommend upper GI endoscopy every 1 to 3 years.
  • Other Lynch-associated cancers: Surveillance is not recommended due to the low sensitivity and specificity. (Although there are insufficient data supporting surveillance for other target organs, it may be considered in the context of family history.)

    Additional Resources
    The fully published guideline2 and more information, including Data Supplements (with reprinted ESMO recommendations and diagnosis algorithms), a Methodology Supplement, slide sets, and clinical tools and resources, are available at www.asco.org/endorsements/HereditaryCRC. Patient information is available at www.cancer.net.

0 comments :

Post a Comment

Your comments?